Know Before You Go

With Thanks to DIGITAL

WECAN Capital Partners is grateful to DIGITAL (Canada's Global Innovation Cluster for Digital Technologies) for the invitation to present at the webinar titled 'Expanding Horizons: Pathways for Canadian Tech to Scale in Europe' on 5 February 2026. The session brought together leaders from WECAN and DIGITAL to explore how Canadian technology companies can build durable European positions through disciplined preparation rather than opportunistic travel.

Particular thanks are owed to the organisers at DIGITAL and to the fellow panellists who shaped a substantive conversation: Jenn Mielguj, Director of IP at DIGITAL; Chris Doody, Director of Investment Oversight at DIGITAL; and Costas Kapsouropoulos, Digital & Science Counsellor at the Delegation of the EU to Canada. WECAN was represented on the panel by Robert Painchaud and Richard Sealy, Partners, and Philip Staff, Partner.

The thread running through the presentation was that European success is determined before a Canadian company boards its first trans-Atlantic flight. It begins with an honest diagnosis of the company's business archetype, which dictates the capital mandate thesis, which dictates the pathway to Europe. The notes that follow expand on that framework, together with the supporting evidence and practical guidance that a short webinar format does not accommodate.

"Archetype, mandate, pathway — in that order — is how companies that scale in Europe successfully differ from those that merely travel. Know before you go is not a slogan. It is risk management."

The Business Tourist Problem

"Why do so many well-funded, well-led Canadian scale-ups stall in Europe within eighteen months of arrival?"

European expansion often fails for a more fundamental reason: a lack of clarity on the company’s strategic purpose in Europe. WECAN's work across Canadian outbound mandates shows that success depends on understanding where the business fits within a European value chain. When that position is clearly defined, companies can shape their pathway, select the right partners and build a credible capital thesis. This clarity is what European banks, investors and corporate partners want to see to when evaluating opportunities with Canadian businesses.

Puting this very tactically, Growth-stage partners in Europe will look for conviction, committment, a defined use of growth funds and evidence of durable positioning in the target market.

The WECAN Framework — Archetype, Mandate, Pathway

WECAN's framework imposes three questions, in a specific order, on every outbound Canadian company we advise. Skipping or reordering them is the single largest predictor of failed European expansion.

01 Diagnose the Archetype Step One · Know Before You Go

A company's archetype is the shape of its business as European capital and customers will perceive it, not as its North American investors describe it. We recognise five dominant archetypes in Canadian tech outbound flow.

The Platform Scaler. SaaS or marketplace with proven North American unit economics, seeking to replicate a repeatable motion across multiple European geographies. Capital need is large, late, and growth-oriented. Europe is treated as a set of sequenced countries, not a single market.

The Deep-Tech Specialist. Hard-science or advanced engineering IP (quantum, photonics, advanced materials, industrial AI). Commercial traction is thin but technical moat is significant. European public and strategic capital is disproportionately attractive here. Sovereignty narratives matter.

The Regulated-Market Entrant. Health tech, fintech, govtech, or climate tech where the product cannot ship without a European regulatory pathway (MDR, DORA, EU AI Act, CSRD). Pathway sequencing — regulation before revenue — is non-negotiable.

The Enterprise Anchor. Sells six- or seven-figure contracts to large European enterprises or public-sector buyers. Success depends on landing one or two reference logos per geography; capital is often best paired with venture clienting or corporate partnership rather than pure equity.

The Consumer/Prosumer Brand. Brand-led, marketing-intensive, and culturally sensitive. Europe is least forgiving of North American tone, pricing, and channel assumptions. Capital is typically later-stage and partnership-adjacent.

An honest archetype diagnosis is frequently uncomfortable. Many Canadian founders describe themselves as Platform Scalers when the evidence supports Enterprise Anchor or Regulated-Market Entrant. The capital strategy implications of that distinction are enormous.

02 Define the Capital Mandate Thesis Step Two · Know Before You Go

The capital mandate thesis is a written, board-endorsed document that answers four questions: How much capital do we need in Europe, over what period, from what type of investor, and in exchange for what governance? It is not a fundraising deck. It is the governance artefact that prevents mandate drift.

The thesis must be archetype-consistent. A Deep-Tech Specialist with a €2M EIC Accelerator grant and a strategic corporate partner has a coherent thesis. The same company pursuing a €25M Series B from a generalist London fund does not. The mismatch will be discovered — usually late, usually expensively.

WECAN insists that the mandate thesis explicitly names: the target lead investor profile by geography and fund type; the non-dilutive stack (grants, tax credits, venture debt, venture clienting) that will be pursued in parallel; the dilution ceiling the board will accept; and the governance concessions — board seats, reserved matters, reporting cadence — that are pre-approved versus contested.

03 Sequence the Pathway to Europe Step Three · Know Before You Go

Only once the archetype is diagnosed and the mandate thesis is written should a physical pathway to Europe be sequenced. The pathway is the operational plan: which country first, which customers first, which regulatory filings first, which hires first, which capital closes first. It is archetype-specific and mandate-constrained.

The pathway is not a travel itinerary. It is a 24- to 36-month sequencing plan with gates, decision points, and capital triggers. It is the document WECAN spends the most time on with its clients, and the one most frequently missing when we are first engaged.

"The pathway is not a travel itinerary. It is a 24- to 36-month sequencing plan with gates, decision points, and capital triggers."

Pathway Patterns by Archetype

The following archetype-specific pathways are drawn from WECAN engagements and reflect what actually works in the current European market, not what looks attractive on a map.

Platform Scaler

Begin in a single English-language beachhead — typically the UK, Ireland, or the Netherlands — and resist the temptation to launch simultaneously across DACH, Nordics, and Southern Europe. Secure a European lead investor based in the beachhead country before hiring a Country General Manager. European funds expect to help recruit that hire, not inherit it. Reach €2–3M of European ARR before attempting a second geography. Accept a European board observer at Series A and a full board seat at Series B. Plan for quarterly in-person European board meetings.

Deep-Tech Specialist

EIC Accelerator, Horizon Europe consortium participation, or a national innovation agency (Bpifrance, SPRIND, Vinnova) is typically the correct first cheque — not a VC. An EU operating subsidiary is often required to receive non-dilutive capital; establish it only when the first grant or programme requires it, not before. European industrial CVCs (Siemens, Bosch, BASF, Airbus Ventures) are disproportionately active in deep tech and bring both capital and customer pull. A single lighthouse European reference customer — ideally one named in the grant narrative — creates a durable fundraising story for the next 24 months.

Regulated-Market Entrant

MDR/IVDR, DORA, EU AI Act, and CSRD pathways must be diagnosed and budgeted before any commercial target is set. Notified Body selection alone can add 9–12 months. For health tech, reimbursement routes (Germany DiGA, France PECAN, NHS MedTech Funding Mandate) define which country you enter first, not the other way around. Non-dilutive plus specialist health-tech VC (Sofinnova, Earlybird Health, LSP, MTIP) before generalist growth capital. Model the 12–18 month gap between pilot completion and at-scale procurement. This gap is the most common failure point we see.

Enterprise Anchor

Identify two or three target enterprise or public-sector customers per geography before choosing the geography. Pathways follow logos, not maps. German Mittelstand and Nordic enterprises increasingly offer paid pilots without taking equity — a strictly better form of validation than a small seed round. A senior European enterprise seller is typically hire number one, before a country GM, before a marketing lead, before an office. Venture debt and corporate partnership capital are often more efficient than equity at this stage; WECAN frequently recommends blended structures.

Consumer/Prosumer Brand

Pricing, tone, and channel assumptions from the North American market will not translate. Budget for localisation as a product cost, not a marketing cost. Win one European country convincingly before touching a second. Consumer brands that spread thin in Europe almost always retrench. Later-stage growth equity and family-office capital — particularly from continental European family offices with consumer-brand heritage — is the realistic target.

The European Capital Landscape in Brief

A full treatment of European capital structure is beyond the scope of this insight, but the headlines every Canadian founder should internalise before travelling are the following.

Europe is not a single market. It is fifteen to twenty distinct venture ecosystems with different specialisations, governance norms, and investment theses. 'European VC' is a category error.

The home-market bias is real. European institutional LPs typically mandate their VCs to deploy 70–90% of capital within a defined geography. A London fund with a 'European' label may have only 20–30% available for non-UK investments.

Non-dilutive capital is unusually deep. €15–20B per year is deployed across EIC, Horizon Europe, and national innovation agencies. For the right archetype, this is the cheapest and most strategic first cheque available anywhere in the world.

The bar is higher than in 2021. Valuations are 30–50% below peak, structured equity is back, and profitability discussions now happen at Series A, not Series C.

Diligence is longer and more formal. Six to nine months from first meeting to wire transfer is standard for rounds above €10M. European VCs will run parallel diligence on business fundamentals and on regulatory or commercial viability, often at the company's expense.

Sources: PitchBook European VC Report 2024; Invest Europe Annual Survey 2023; CVCA 2023 Data; EIC Accelerator programme data; Preqin European PE Report Q4 2023.

Questions WECAN Asks Before Accepting a European Mandate

These are the questions we put to Canadian companies at the first meeting. They are reproduced here because they are the questions every board should be asking before committing capital to a European expansion.

#	Question
01	Which of the five archetypes best describes your business as a European investor would see it — not as you would describe it?
02	If your archetype diagnosis is uncomfortable, what would have to be true for the more comfortable diagnosis to be correct, and is it?
03	Why is now the right moment to enter Europe, as opposed to eighteen months from now with a stronger North American base?
04	Which single European country will you win first, and what evidence do you have that you can win it?
05	What is the smallest amount of European capital that gets you to a defensible next milestone, and from which type of investor should it come?
06	Which governance concessions — board seats, reserved matters, reporting — has your board already pre-approved, and which are contested?
07	What is your plan for the 12–18 month gap between pilot completion and at-scale procurement, and who is funding it?
08	Who on your team will live in Europe, when, and with what mandate?

"The most successful Canadian companies in Europe treat their European capital strategy as a distinct business unit with its own archetype, its own mandate, its own pathway, its own P&L, and its own board-level attention. They are not business tourists. They know before they go."

#	Example Preparatory Steps
01	Reach board-level agreement on which business archetype the company represents as a European investor or customer would see it. Without this alignment, every subsequent capital and market decision risks being built on the wrong foundation.
02	Produce a written, board-endorsed capital mandate thesis that defines how much European capital is needed, over what period, from what type of investor, and on what governance terms. European diligence is slow and formal, and arriving without this document signals unpreparedness to exactly the investors who move most deliberately.
03	Build a sequenced operational pathway to Europe spanning two to three years, with named countries, capital triggers, and decision gates. A calendar of European meetings is not a strategy; a gated plan turns intention into something an investor or board can hold the company accountable to.
04	Understand, with professional advice, which European regulatory frameworks apply to the business and what they will cost in time and money. Regulatory timelines in Europe are long, largely non-negotiable, and carry real consequences for runway; discovering this after committing to a market is one of the most common and expensive mistakes we see.
05	Develop a considered shortlist of European investor targets, organised by geography and fund type, ranked by how well each candidate fits the mandate thesis rather than by brand visibility. Approaching the wrong investors wastes time that cannot be recovered and can close doors that are difficult to reopen.
06	Identify and engage two or three individuals with genuine operational credibility in the target European market, ideally on a formal rather than informal basis. In-region standing is one of the most reliable shortcuts to serious commercial and investor conversations, and it cannot be improvised once the company has arrived.
07	Build a multi-year European financial model constructed country by country, to the standard European institutional investors expect to see. A North American deck with a European chapter appended rarely survives diligence; a properly constructed model signals the discipline that opens the next conversation.
08	Make a deliberate, documented decision on whether and when to establish a European entity — and in which jurisdiction. This choice carries tax, regulatory, and capital structure consequences that compound over time, and deferring it is itself a decision, rarely the optimal one.